OKYO Pharma (OKYO) Share Price, News & Analysis

Company Overview

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 1.40 to 1.40
• 52-Week Range: N/A
• Volume: 364,142 shs
• Average Volume: 431,999 shs
• Market Capitalization: £23.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OKYO Stock Analysis - Frequently Asked Questions

How do I buy shares of OKYO Pharma?

Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of OKYO Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Avino Silver & Gold Mines (ASM), AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Aurora Cannabis (ACB), Allied Gaming & Entertainment (AGAE) and Academy Sports and Outdoors (ASO).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:OKYO
• CIK: N/A
• Web: www.okyopharma.com
• Phone: 44 20 7495 2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£6.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -397.13%
• Return on Assets: -154.72%

Debt

• Debt-to-Equity Ratio: 1.65
• Current Ratio: 0.83
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 28.00
• Book Value: GBX (1) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,660,000,000
• Free Float: N/A
• Market Cap: £23.24 million
• Optionable: Not Optionable
• Beta: -0.06